Open AccessDonafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
Author(s) -
Francesca Negri,
Camillo Porta
Publication year - 2021
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2021.564
Subject(s) - medicine , hepatocellular carcinoma , drug , intensive care medicine , drug development , standard of care , oncology , pharmacology
Not available